Quick Answer
GYRE THERAPEUTICS, INC. reported Revenue (ASC 606) of $116.59 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $116.59M | +10.2% |
| 2024 | $105.76M | -6.8% |
| 2023 | $113.45M | +10.9% |
| 2022 | $102.29M | +1294.0% |
| 2021 | $7.34M | -65.0% |
| 2020 | $20.95M | +349033.3% |
| 2018 | $6.0K | -99.4% |
| 2017 | $1.02M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.56M | +19.9% | +14.2% |
| June 30, 2025 | $26.77M | +6.1% | +21.4% |
| March 31, 2025 | $22.06M | -18.8% | -13.5% |
| September 30, 2024 | $25.49M | -20.5% | +1.0% |
| June 30, 2024 | $25.23M | -14.0% | -7.2% |
| March 31, 2024 | $27.17M | +9.0% | -15.2% |
| September 30, 2023 | $32.04M | — | +9.3% |
| June 30, 2023 | $29.33M | — | +17.6% |
- GYRE THERAPEUTICS, INC. showed an increase of +10.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2025 period, GYRE THERAPEUTICS, INC.’s revenue (asc 606) has grown by 11352.7% (from $1.02 million to $116.59 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: